Wieloośrodkowa prospektywna kohorta sarkoidozy sercowej (CHASM-CS)
Wieloośrodkowe prospektywne badanie kohortowe dotyczące sarkoidozy sercowej
Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS) of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon. A Canadian physician survey found that most physicians do not investigate for CS as a possibility in these situations. Thus many patients with clinically important CS are going un-diagnosed. A study from Finland showed that missing the diagnosis of CS in these patients' leads to significant mortality and morbidity.
There are no published clinical consensus guidelines on treatment of CS. Corticosteroid therapy is advocated by most experts. This is based on very modest data from small retrospective observational studies using variable definitions of clinical response. The effect of corticosteroid treatment on the clinical course of CS has not been studied in prospective studies and will be one of the aims of this project. Recent physician surveys regarding CS, in Canada and the US, found that current clinical practice varies widely. The 2008 American College of Cardiology/American Heart Association/Heart Rhythm society guidelines recommend implantation of a defibrillator (Class IIa recommendation) to prevent sudden cardiac death. The most recent Canadian device therapy guidelines do not mention CS.
A multi-center collaborative approach to study CS is greatly needed." The investigators propose exactly that i.e. a multi-center prospective cohort to start to answer clinical questions. The investigators have formed the CANADIAN CARDIAC SARCOIDOSIS RESEARCH GROUP. The group includes respirologists with an interest in sarcoidosis, cardiac electrophysiologists, cardiac imaging specialists with extensive experience in imaging of sarcoidosis and biostatisticians. The research will be in two phases; a registry of current diagnostic approaches, treatment and prognosis, and a randomized clinical trial of the effect of corticosteroid treatment on the clinical course of cardiac sarcoidosis.
Przegląd badań
Status
Status
Warunki
Warunki
Szczegółowy opis
Baseline assessment of Clinically Manifest CS patients consists of: history, echocardiogram, ECG, chest CT scan, FDG-PET scan, blood for biomarkers within 2 months of the PET scan, cardiac MRI and possibly a signal average ECG and biopsy (encouraged-either endomyocardial or extra-cardiac).
Follow-up and clinical management of clinically manifest patients diagnosed with CS will occur at 3-6 months with a repeat FDG-PET scan and blood biomarkers. Follow-up will then be annually with an echo and ECG. Treatment with steroids/immunosuppressants and device therapy will be at the discretion of the treating physician.
Baseline assessment of patients diagnosed with extra-cardiac sarcoidosis and being screened for CS consists of: history, echocardiogram, ECG, holter, chest CT scan, biopsy, and cardiac MRI (CMR). If the CMR is suggestive of CS the patient will be have a FDG-PET scan done and be followed as a Clinically Silent patient. They will be contacted every 2 years. If the CMR is negative the patient will be followed as a extra-cardiac sarcoidosis patient with no evidence of CS and be in the control group. They will be contacted at 5 years and at the time of study completion.
All patients will be followed until the last patient recruited has been followed for 4 years.
The occurrence of the primary and secondary outcomes will be assessed in treated and untreated patients.
There will be 2 imaging core labs. The PET core lab will be located at UOHI under the direction of Dr. Robert Beanlands. The CMR core lab will be under the direction of Dr. Mathias Friedrich (McGill University). All scans will be read in the core labs by physicians who are blinded to the clinical details of the patients.
The Biomarker core lab will be at The University of Ottawa Heart Institute under the leadership of Dr P Liu.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Janine E Ryan, BA(H), CCRP
- Numer telefonu: 17077 613-696-7000
- E-mail: jryan@ottawaheart.ca
Kopia zapasowa kontaktu do badania
- Nazwa: David Birnie, MD
- Numer telefonu: 613-696-7269
- E-mail: dbirnie@ottawaheart.ca
Lokalizacje studiów
-
-
-
Sapporo, Japonia, 060-8638
- Rekrutacyjny
- Hokkaido University
-
Kontakt:
- Ichizo Tsujino, MD
- Numer telefonu: 81-11-706-5911
- E-mail: itsujino@med.hokudai.ac.jp
-
Główny śledczy:
- Ichizo Tsujino, MD
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 2T9
- Rekrutacyjny
- Libin Cardiovascular Institute of Alberta
-
Główny śledczy:
- Russell Quinn, MD
-
Kontakt:
- Russell Quinn, MD
-
Edmonton, Alberta, Kanada, T6G 2B7
- Rekrutacyjny
- University of Alberta Hospital
-
Kontakt:
- Tomascz Hruczkowski, MD
-
Główny śledczy:
- Tomascz Hruczkowski, MD
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 1M9
- Rekrutacyjny
- St. Paul's Hospital
-
Kontakt:
- Shanta Chakrabarti, MD
-
Główny śledczy:
- Shanta Chakrabarti, MD
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3H 3A7
- Rekrutacyjny
- QEII Health Sciences Center
-
Główny śledczy:
- Ciorsti MacIntyre, MD
-
Kontakt:
- Kim Anderson, MD
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8L 2X2
- Rekrutacyjny
- Hamilton Health Sciences Centre
-
Główny śledczy:
- Jeff Healey, MD
-
Kontakt:
- Gerard Cox, MD
-
Kontakt:
- Jeff Healey, MD
-
London, Ontario, Kanada, N6A 5A5
- Rekrutacyjny
- London Health Sciences Centre
-
Kontakt:
- Lorne Gula, MD
-
Główny śledczy:
- Lorne Gula, MD
-
Newmarket, Ontario, Kanada, L3Y 2P9
- Rekrutacyjny
- Southlake Regional Health Centre
-
Kontakt:
- Bernice Tsang, MD
-
Główny śledczy:
- Bernice Tsang, MD
-
Ottawa, Ontario, Kanada, K1Y 4W7
- Rekrutacyjny
- University of Ottawa Heart Institute
-
Kontakt:
- Tammy Knight
- Numer telefonu: 19080 613-696-7000
- E-mail: tknight@ottawaheart.ca
-
Główny śledczy:
- David Birnie, MD
-
Kontakt:
- Janine E Ryan, BA H
- Numer telefonu: 17077 613-696-7000
- E-mail: jryan@ottawaheart.ca
-
Toronto, Ontario, Kanada, M5G 2C4
- Rekrutacyjny
- Toronto General Hospital
-
Kontakt:
- Andrew Ha, MD
-
Główny śledczy:
- Andrew Ha, MD
-
-
Quebec
-
Montreal, Quebec, Kanada, H1T 1C8
- Rekrutacyjny
- Montreal Heart Institute
-
Kontakt:
- Lena Rivard, MD
-
Główny śledczy:
- Lena Rivard, MD
-
Montreal, Quebec, Kanada, H3G 1A4
- Rekrutacyjny
- McGill University Health Centre
-
Kontakt:
- Fiorella Rafti
-
Główny śledczy:
- Martin L Bernier, MD
-
Montreal, Quebec, Kanada, H2W 1T8
- Jeszcze nie rekrutacja
- Centre Hospitalier de l"Universite de Montreal-Hotel Dieu
-
Kontakt:
- Julie Fleury, RN
-
Główny śledczy:
- Benoit Coutu, MD
-
-
Saskatchewan
-
Regina, Saskatchewan, Kanada, S4P 0W5
- Rekrutacyjny
- Prairie Vascular Research Inc-Regina General Hospital
-
Kontakt:
- Kendra Townsend
- E-mail: Ktownsend.pvri@gmail.com
-
Główny śledczy:
- Andrea Lavoie, MD
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Electrophysiology Service patients
Opis
Inclusion Criteria:
To diagnose Clinically Manifest CS all following criteria must be met:
(i) Positive biopsy* for Sarcoid (either EMB or extra-cardiac) AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis AND (iii) one or more of the following clinical features:
- advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
- non- sustained or sustained ventricular arrhythmia
- ventricular dysfunction (LVEF < 50% and/or RVEF < 40%) AND (iv) No alternative explanation for clinical features AND (v) FDG-PET suggestive of active CS
To diagnose clinically silent CS all of the following criteria must be met
(i) Biopsy proven extra-cardiac sarcoidosis
AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis
AND (iii) CMR suggestive of cardiac sarcoidosis
AND (iv) Does not have criteria for clinically manifest CS ie. should not have any of following
- advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
- non- sustained or sustained ventricular arrhythmia
- ventricular dysfunction (LVEF < 50% and/or RVEF < 40%)
Patients with negative CMR will be designated as 'extra-cardiac sarcoidosis with no evidence of CS' and followed as control
Exclusion Criteria:
- unable or unwilling to provide informed consent
- patients who are pregnant or lactating
- patients with known claustrophobia
- age < 18 years
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Liczba grup / kohort
Kohorty i interwencje
Grupa / KohortaGrupa / Kohorta |
|---|
|
CS screened as underlying etiology
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Primary Outcome for ALL Patients
Ramy czasowe: Through study completion, on average 10 years
|
The primary outcome is a composite of cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation. Heart failure hospitalization is defined as admission to hospital > 24 hours and received treatment for heart failure. Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Secondary Outcomes for ALL Patients
Ramy czasowe: Through study completion, on average 10 years
|
1. Total mortality Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for ALL Patients
Ramy czasowe: Through study completion, on average 10 years
|
2. Individual components of primary outcome (cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation) Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Ramy czasowe: Through study completion, on average 10 years
|
1. Change in LVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Ramy czasowe: Through study completion, on average 10 years
|
2. Change in RVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Ramy czasowe: Through study completion, on average 10 years
|
3. Change in cardiac disease activity from pre-treatment to on treatment and post-treatment cessation as assessed by FDG-PET Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Ramy czasowe: Through study completion, on average 10 years
|
4. Atrial fibrillation burden (from ICD and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Ramy czasowe: Through study completion, on average 10 years
|
5. Ventricular arrhythmia burden, including PVC burden (from ICD diagnostics and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Ramy czasowe: Through study completion, on average 10 years
|
6. Appropriate ICD therapy Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Ramy czasowe: Through study completion, on average 10 years
|
7. Percentage (%) of ventricular pacing Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
Ramy czasowe: Through study completion, on average 10 years
|
8. AV nodal function Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Silent Disease and Control Patients
Ramy czasowe: Through study completion, on average 10 years
|
1. Development of Clinically Manifest CS Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Śledczy
Śledczy
- Główny śledczy: Pablo Nery, MD, Ottawa Heart Institute Research Corporation
- Główny śledczy: Rob Beanlands, MD, Ottawa Heart Institute Research Corporation
- Główny śledczy: David Birnie, MD, Ottawa Heart Institute Research Corporation
Publikacje i pomocne linki
Publikacje ogólne
- Weng W, Wiefels C, Chakrabarti S, Nery PB, Celiker-Guler E, Healey JS, Hruczkowski TW, Quinn FR, Promislow S, Medor MC, Spence S, Odabashian R, Alqarawi W, Juneau D, de Kemp R, Leung E, Beanlands R, Birnie D. Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes. J Am Heart Assoc. 2020 Sep;9(17):e017086. doi: 10.1161/JAHA.120.017086. Epub 2020 Aug 20.
- Martineau P, Pelletier-Galarneau M, Juneau D, Leung E, Nery PB, de Kemp R, Beanlands R, Birnie D. Imaging Cardiac Sarcoidosis With FLT-PET Compared With FDG/Perfusion-PET: A Prospective Pilot Study. JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 1):2280-2281. doi: 10.1016/j.jcmg.2019.06.020. Epub 2019 Aug 14. No abstract available.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Szacowany)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- UOHI-04
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .